| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $42.1M | +72.5% |
| SG&A Expense | $33.2M | +7.7% |
| Operating Income | -$75.2M | -36.3% |
| Pre-tax Income | -$68.7M | -31.0% |
| Net Income | -$68.7M | -31.0% |
| EPS (Basic) | -$1.06 | -76.7% |
| EPS (Diluted) | -$1.06 | -76.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $109.4M | -38.0% |
| Current Assets | $112.3M | -37.2% |
| Total Assets | $113.9M | -36.5% |
| Current Liabilities | $12.4M | -36.4% |
| Total Liabilities | $12.4M | -36.4% |
| Stockholders' Equity | $101.5M | -30.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$64.8M | -130.9% |
| Capital Expenditures | $113K | +50.7% |
| Investing Cash Flow | -$113K | +97.8% |
| Financing Cash Flow | -$2.2M | -102.0% |
| Free Cash Flow | -$64.9M | -130.6% |